EIF4A2 Antibody

What is EIF4A2 and why is it important in molecular biology research?

EIF4A2 (Eukaryotic Translation Initiation Factor 4A2) is a member of the DEAD-box RNA helicase family that plays a critical role in mRNA translation initiation. Unlike its highly homologous paralog eIF4A1, eIF4A2 functions as a negative regulator of mRNA translation, particularly affecting the synthesis of membrane and secretory proteins . This factor is particularly important in molecular biology research because it represents a distinct regulatory layer in the translation machinery that influences diverse cellular processes including proliferation, immune responses, and tumor microenvironment formation. Recent studies have revealed that eIF4A2 also has unexpected roles in ribosome biogenesis, specifically controlling 40S ribosome subunit formation . Understanding EIF4A2 function provides critical insights into translational control mechanisms that govern cell fate decisions in both normal development and disease states.

How does EIF4A2 antibody reactivity differ across species?

EIF4A2 antibodies demonstrate variability in cross-species reactivity depending on the specific epitope targeted and the antibody's production methodology. Based on the available data, many commercially available EIF4A2 antibodies show reactivity across human, rat, and mouse samples . This cross-reactivity is facilitated by the high sequence conservation of EIF4A2 across mammalian species. For example, antibody ABIN3043426, which targets an N-terminal epitope (amino acids 5-31), demonstrates confirmed reactivity across all three species in Western blotting and immunohistochemistry applications . Some EIF4A2 antibodies extend their reactivity to additional species such as cow and pig, particularly those targeting conserved domains . When selecting an antibody for cross-species applications, researchers should specifically verify that the epitope sequence is conserved in their target species and that the antibody has been experimentally validated for their intended application in that species.

What are the main applications of EIF4A2 antibodies in research?

EIF4A2 antibodies serve as essential tools across multiple experimental methodologies in molecular and cellular biology research. The primary applications include:

• Western Blotting (WB): For detection and quantification of EIF4A2 protein expression levels in cell or tissue lysates, typically using concentrations of 0.1-0.5 μg/mL for optimal results .

• Immunohistochemistry (IHC): Both paraffin-embedded (IHC-P) and frozen section protocols can be used to visualize EIF4A2 localization in tissue contexts, with recommended antibody concentrations of 0.5-1 μg/mL .

• Immunofluorescence (IF): For subcellular localization studies examining EIF4A2 distribution patterns.

• RNA Immunoprecipitation (RIP): To identify RNA species specifically associated with EIF4A2 protein complexes .

• Immunoprecipitation (IP): For isolation of EIF4A2 and its interacting protein partners.

• Flow Cytometry (FACS): For quantitative analysis of EIF4A2 expression at the single-cell level .

These applications have been instrumental in revealing EIF4A2's roles in translation regulation, B-cell development, and tumor microenvironment formation .

What are the optimal protocols for using EIF4A2 antibodies in immunohistochemistry?

For successful immunohistochemical detection of EIF4A2 in tissue samples, follow these methodological recommendations:

• Sample Preparation:

  • Fixation: 10% neutral buffered formalin for 24-48 hours

  • Processing: Standard paraffin embedding

  • Sectioning: 4-5 μm thickness sections mounted on positively charged slides

• Epitope Retrieval (Critical Step):

  • Method: Heat-induced epitope retrieval is essential

  • Solution: 10 mM citrate buffer (pH 6.0)

  • Duration: 20 minutes at boiling temperature

  • Cooling: Allow slides to cool to room temperature (approximately 20 minutes)

• Blocking and Antibody Application:

  • Peroxidase blocking: 3% hydrogen peroxide for 10 minutes

  • Protein blocking: 2-5% normal serum (species matched to secondary antibody)

  • Primary antibody: Apply EIF4A2 antibody at 0.5-1 μg/mL concentration

  • Incubation: Overnight at 4°C or 1-2 hours at room temperature

• Detection System:

  • Use compatible secondary antibody and detection system (e.g., HRP-polymer systems)

  • DAB development: 1-5 minutes (monitor microscopically)

  • Counterstain: Hematoxylin (1-2 minutes)

• Controls:

  • Include positive control tissues with known EIF4A2 expression

  • Include negative controls (primary antibody omission)

  • Consider knockout/knockdown validation when possible

This protocol has been optimized to ensure specific staining while minimizing background, particularly important when studying the differential expression of EIF4A2 across developmental stages or in disease models .

How can researchers optimize Western blot protocols for EIF4A2 detection?

Optimizing Western blot protocols for EIF4A2 detection requires attention to several critical parameters:

• Sample Preparation:

  • Lysis buffer: RIPA buffer supplemented with protease inhibitors

  • Protein concentration: Standardize to 20-40 μg of total protein per lane

  • Denaturation: Heat samples at 95°C for 5 minutes in reducing sample buffer

• Gel Electrophoresis and Transfer:

  • Gel percentage: 10-12% polyacrylamide gels are optimal for resolving EIF4A2 (~46 kDa)

  • Run conditions: 100-120V constant voltage

  • Transfer: Wet transfer at 100V for 60-90 minutes or overnight at 30V (4°C)

  • Membrane: PVDF membranes typically yield better results than nitrocellulose

• Antibody Incubation:

  • Blocking: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • Primary antibody: Use EIF4A2 antibody at concentration of 0.1-0.5 μg/mL

  • Incubation: Overnight at 4°C with gentle rocking

  • Washing: 3 x 10 minutes in TBST

• Detection Optimization:

  • Secondary antibody: HRP-conjugated anti-rabbit IgG (1:5000-1:10000)

  • Enhanced chemiluminescence detection: Use high-sensitivity ECL substrates

  • Exposure: Start with 30-second exposure and adjust as needed

• Validation and Controls:

  • Positive control: Lysates from tissues/cells known to express EIF4A2

  • Negative control: Samples from EIF4A2 knockout models when available

  • Loading control: Probe for housekeeping proteins (β-actin, GAPDH)

A critical consideration for EIF4A2 detection is distinguishing it from the highly homologous EIF4A1 protein. Using antibodies that target non-conserved regions, particularly at the N-terminus (amino acids 5-31) or C-terminus (amino acids 333-360), helps ensure specificity .

What controls should be included when validating EIF4A2 antibody specificity?

Rigorous validation of EIF4A2 antibody specificity is essential for reliable experimental results, especially considering the high sequence similarity with EIF4A1. The following controls should be implemented:

• Genetic Models:

  • EIF4A2 knockout/knockdown samples: Essential negative controls that should show absence or significant reduction of target band/signal

  • Conditional knockout models: Validate antibody in tissues from Eif4a2 fl/fl;CD19Cre or Eif4a2 fl/fl;Mb1Cre mouse models

  • Overexpression systems: Cells transfected with EIF4A2 expression constructs should show increased signal

• Peptide Competition:

  • Pre-incubate antibody with the immunizing peptide (N-terminal sequence SADYNREHGGPEGMDPDGVIESNWNEI)

  • This should abolish or significantly reduce specific signal

• Cross-Reactivity Assessment:

  • Test against EIF4A1 expression systems to confirm no cross-reactivity

  • Particularly important as the antibody documentation states "No cross reactivity with other proteins"

• Multi-technique Validation:

  • Confirm signal with at least two different detection methods (e.g., WB and IHC)

  • Use antibodies targeting different epitopes of EIF4A2 (N-terminal vs. C-terminal)

• Expression Pattern Correlation:

  • Compare protein detection patterns with known mRNA expression profiles

  • Verify concordance with published expression patterns in B-cell development (increasing from early to late stages)

• Specificity in Multiple Species:

  • If claiming multi-species reactivity, validate in human, mouse, and rat samples

  • Confirm expected molecular weight differences if any exist between species

These validation approaches collectively provide strong evidence for antibody specificity, which is particularly crucial when studying EIF4A2's unique functions in translation regulation and ribosome biogenesis that differentiate it from EIF4A1 .

How can researchers differentiate between EIF4A1 and EIF4A2 in experimental systems?

• Antibody Selection:

  • Use antibodies targeting non-conserved regions, particularly the N-terminus (aa 5-31) for EIF4A2

  • Validate antibody specificity using genetic models where either EIF4A1 or EIF4A2 is depleted

  • Perform side-by-side Western blots with specific antibodies against each paralog

• Expression Pattern Analysis:

  • Leverage their distinct expression patterns during cellular processes

  • In B-cell development, EIF4A1 expression is high in early stages (Fraction C) and decreases afterward, while EIF4A2 gradually increases and peaks in mature B cells

  • Upon B-cell activation, EIF4A1 is strongly induced while EIF4A2 shows initial upregulation followed by decrease by 48 hours

• Functional Assessment:

  • Analyze global protein synthesis (primarily affected by EIF4A1)

  • Examine 18S ribosomal RNA and 40S ribosome subunit biogenesis (specifically regulated by EIF4A2)

  • Assess membrane/secretory protein synthesis (particularly suppressed by EIF4A2)

• Genetic Approaches:

  • Use paralog-specific knockdown/knockout systems

  • Employ conditional knockout models such as Eif4a1 fl/fl;CD19Cre versus Eif4a2 fl/fl;CD19Cre

  • Analyze distinct phenotypes: EIF4A1 and EIF4A2 show different roles in T-cell-independent antibody responses

• Target mRNA Association:

  • Perform RNA immunoprecipitation (RIP) assays to identify distinct mRNA populations associated with each paralog

  • EIF4A2 preferentially regulates mRNAs encoding membrane and secretory proteins

Understanding these differences is crucial for interpreting experimental results correctly, especially when studying translation regulation in development, immunity, and cancer contexts.

What is the role of EIF4A2 in cancer development and how can antibodies help elucidate these mechanisms?

EIF4A2 plays a complex and sometimes context-dependent role in cancer development, with emerging evidence suggesting it functions as a significant regulator of tumor initiation and progression. EIF4A2 antibodies serve as critical tools for investigating these mechanisms.

• Tumor Microenvironment Formation:

  • EIF4A2 functions as a negative regulator of membrane/secretory protein synthesis

  • EIF4A2 deletion upregulates synthesis of these proteins, leading to increased integrin degradation

  • This compromises the formation of extracellular matrix (ECM)-rich tumor initiation niches, which are crucial for the progression from non-proliferative/senescent-like hepatocytes to hepatocellular carcinoma (HCC)

  • Immunohistochemistry using EIF4A2 antibodies can visualize spatial expression patterns within tumor microenvironments

• Translational Regulation Mechanisms:

  • EIF4A2 antibodies enable immunoprecipitation studies to identify mRNAs selectively regulated by EIF4A2

  • Western blot analysis can reveal how EIF4A2 levels correlate with expression of ECM proteins and translation regulators

  • Immunofluorescence microscopy with EIF4A2 antibodies can determine subcellular localization changes during cancer progression

• Early Tumorigenesis:

  • EIF4A2 appears critical during the oncogene-induced senescence phase of HCC development

  • Antibody-based techniques can monitor EIF4A2 expression dynamics during this transition

  • Spatial and temporal expression patterns reveal how translation regulation influences tumor initiation vs. progression

• Therapeutic Implications:

  • Pharmacological inhibition of mRNA translation in EIF4A2-deleted systems can restore ECM deposition and reinstate HCC progression

  • Antibodies enable verification of EIF4A2 target engagement in drug development

  • Immunohistochemistry of patient samples can potentially identify cancer subtypes based on EIF4A2 expression patterns

The paradoxical finding that EIF4A2 deletion can actually compromise tumor progression in certain contexts highlights the complex nature of translational regulation in cancer and underscores the importance of precise methodological approaches using well-validated antibodies for studying these mechanisms .

How does EIF4A2 function in immune cell development and responses?

EIF4A2 plays critical and distinctive roles in immune cell development and function, particularly in B cells, as revealed by recent genetic studies:

• B-cell Development:

  • EIF4A2 expression shows a gradual increase during B-cell development, reaching highest levels in mature recirculating B cells (Fraction F)

  • Genetic deletion using Eif4a2 fl/fl;Mb1Cre mice demonstrates that EIF4A2 is essential for early B-cell development

  • Unlike EIF4A1, which primarily controls global protein synthesis, EIF4A2 regulates biogenesis of 18S ribosomal RNA and 40S ribosome subunits

• Humoral Immune Responses:

  • EIF4A2 is critical for both T-cell-dependent and T-cell-independent antibody responses

  • B-cell-specific deletion of EIF4A2 (Eif4a2 fl/fl;CD19Cre mice) impairs:

    • Germinal center B cell formation

    • Plasma cell differentiation

    • Production of antigen-specific antibodies

  • EIF4A2 is required for both TI-1 (e.g., NP-LPS) and TI-2 (e.g., NP-Ficoll) antibody responses, while EIF4A1 is only essential for TI-1 responses

• Cellular Mechanisms:

  • EIF4A2 is dispensable for B-cell activation (normal upregulation of CD83, CD86, and CD69)

  • EIF4A2 is essential for B-cell proliferation, specifically at the G1/S transition during cell cycle progression

  • The distinctive expression patterns of EIF4A2 during immune responses (upregulated at 24h but decreased by 48h after activation) suggest dynamic regulation

• Methodological Applications of EIF4A2 Antibodies:

  • Detecting expression changes during immune cell development stages

  • Monitoring EIF4A2 levels in response to various stimuli (anti-IgM, anti-CD40, IL-4, LPS)

  • Investigating ribosome biogenesis in specific immune cell populations

These findings highlight the non-redundant functions of EIF4A2 in immune responses and provide potential targets for modulating immune function through selective manipulation of translation factors .

What are common troubleshooting issues with EIF4A2 antibodies and how can they be resolved?

Researchers often encounter several challenges when working with EIF4A2 antibodies. Here are common issues and their solutions:

• Cross-Reactivity with EIF4A1:

  • Problem: False positive signals due to EIF4A1 detection (90% sequence homology)

  • Solution: Use antibodies targeting unique regions (aa 5-31, N-term)

  • Validation: Confirm specificity using EIF4A2 knockout samples and peptide competition assays

• Weak Signal in Western Blots:

  • Problem: Insufficient detection of EIF4A2 protein

  • Solutions:

    • Optimize protein extraction methods (use RIPA buffer with protease inhibitors)

    • Increase antibody concentration (up to 0.5 μg/mL)

    • Extend primary antibody incubation (overnight at 4°C)

    • Use high-sensitivity chemiluminescence detection reagents

    • Consider signal amplification techniques

• Background in Immunohistochemistry:

  • Problem: Non-specific staining obscuring specific EIF4A2 signal

  • Solutions:

    • Proper epitope retrieval (boiling in 10 mM citrate buffer, pH 6.0, for 20 minutes)

    • Optimize blocking (5% normal serum matching secondary antibody species)

    • Increase washing steps (3-5 washes of 5 minutes each)

    • Titrate antibody concentration (start with 0.5 μg/mL)

    • Use IgG controls to identify non-specific binding

• Inconsistent Results Across Applications:

  • Problem: Antibody works in one application but not others

  • Solution: Different applications may require different antibody formats or clones

  • Approach: Test multiple antibodies targeting different epitopes (N-terminal vs C-terminal)

• Storage and Stability Issues:

  • Problem: Loss of antibody activity over time

  • Solutions:

    • Avoid repeated freeze-thaw cycles

    • Aliquot reconstituted antibody (500 μg/mL)

    • Store according to manufacturer recommendations (4°C short-term, -20°C long-term)

    • Add preservatives like sodium azide (0.05 mg) for longer storage

• Species-Specific Detection Challenges:

  • Problem: Antibody fails in certain species despite claimed reactivity

  • Solution: Verify epitope conservation across species and optimize protocols for specific species

Implementing these solutions will significantly improve experimental outcomes when working with EIF4A2 antibodies across various applications.

How can researchers quantitatively assess EIF4A2 expression in different experimental contexts?

Accurate quantitative assessment of EIF4A2 expression is crucial for understanding its biological roles. Several methodological approaches can be employed:

• Western Blot Quantification:

  • Standard Curve Method:

    • Prepare serial dilutions of purified EIF4A2 protein or positive control lysate

    • Plot band intensities against known concentrations

    • Interpolate unknown sample values

  • Relative Quantification:

    • Normalize EIF4A2 signal to loading controls (β-actin, GAPDH)

    • Use digital imaging software (ImageJ, Image Lab) for densitometry

    • Apply rolling ball background subtraction for accurate measurements

  • Multiplexed Detection:

    • Use fluorescently-labeled secondary antibodies for simultaneous detection of EIF4A2 and reference proteins

    • Provides better dynamic range than chemiluminescence

• Flow Cytometry:

  • Intracellular Staining Protocol:

    • Fix cells with 4% paraformaldehyde

    • Permeabilize with 0.1% Triton X-100 or saponin-based buffers

    • Use directly conjugated EIF4A2 antibodies or primary-secondary combinations

    • Quantify median fluorescence intensity (MFI)

  • Multiparameter Analysis:

    • Correlate EIF4A2 expression with cell cycle phases (using PI or DAPI)

    • Measure in conjunction with B-cell development markers (B220, CD19, IgM, IgD)

    • Critical for analyzing expression dynamics during B-cell development stages

• Immunohistochemistry Quantification:

  • Digital Pathology Approaches:

    • Use whole slide imaging and AI-assisted analysis

    • Quantify staining intensity (H-score or Allred scoring)

    • Measure percentage of EIF4A2-positive cells in tissue sections

  • Multiplex IHC:

    • Co-stain for EIF4A2 and cell type-specific markers

    • Use multispectral imaging systems for precise quantification

• Quantitative Cell-Based Assays:

  • ELISA-Based Methods:

    • Cell-based ELISA for adherent cells

    • Sandwich ELISA for cell lysates

  • Cell-Based Reporter Systems:

    • Create EIF4A2-luciferase fusion constructs

    • Measure expression through bioluminescence

These quantitative approaches allow researchers to precisely measure EIF4A2 expression changes during B-cell development, immune responses, and cancer progression, enabling correlation with functional outcomes such as ribosome biogenesis and translation regulation .

What emerging technologies are enhancing EIF4A2 antibody applications in research?

Several cutting-edge technologies are transforming how researchers utilize EIF4A2 antibodies, opening new avenues for investigation:

• Proximity Labeling Techniques:

  • BioID and TurboID fusions with EIF4A2 enable identification of proximal proteins in living cells

  • APEX2-EIF4A2 fusions allow spatiotemporal mapping of EIF4A2 interactomes

  • These approaches can reveal differential interaction partners between EIF4A1 and EIF4A2, explaining their distinct biological roles

• Super-Resolution Microscopy:

  • STORM/PALM imaging with fluorophore-conjugated EIF4A2 antibodies achieves nanometer-scale resolution

  • Structured illumination microscopy reveals subcellular localization patterns

  • These techniques can visualize EIF4A2 association with specific subcellular structures during translation regulation and ribosome biogenesis

• Single-Cell Proteomics:

  • Mass cytometry (CyTOF) with metal-conjugated EIF4A2 antibodies enables high-dimensional analysis at single-cell resolution

  • Correlation of EIF4A2 expression with dozens of other proteins simultaneously

  • Particularly valuable for analyzing expression heterogeneity during B-cell development and immune responses

• Spatial Transcriptomics Integration:

  • Combined immunofluorescence and in situ RNA sequencing

  • Correlation of EIF4A2 protein levels with spatially resolved transcriptomes

  • Critical for understanding the formation of tumor microenvironments and ECM deposition

• CRISPR-Based Antibody Validation:

  • Creation of epitope-tagged endogenous EIF4A2 using CRISPR-Cas9

  • Generation of cell lines with EIF4A2 knockout for definitive antibody validation

  • Development of degradation-tagging systems (e.g., dTAG) for rapid EIF4A2 depletion

• Intrabodies and Nanobodies:

  • Development of cell-permeable anti-EIF4A2 antibody fragments

  • Live-cell imaging of endogenous EIF4A2 dynamics

  • Potential for selective inhibition of EIF4A2 function without affecting EIF4A1

These technological advances are enhancing our ability to study EIF4A2's functions with unprecedented precision and will be instrumental in further elucidating its roles in translation regulation, ribosome biogenesis, and disease processes.

How might EIF4A2 research influence therapeutic approaches in cancer and immune disorders?

The emerging understanding of EIF4A2's distinct functions in translation regulation and ribosome biogenesis presents promising avenues for therapeutic development:

• Cancer Therapeutics:

  • Targeted Modulation: Research shows that EIF4A2 deletion compromises ECM-rich tumor initiation niches, suggesting EIF4A2 could be selectively targeted in early tumorigenesis

  • Combination Approaches: Pharmacological inhibition of mRNA translation following EIF4A2 modulation offers a potential strategy to influence tumor microenvironment formation

  • Biomarker Potential: EIF4A2 expression patterns could serve as prognostic indicators or predictors of treatment response

  • Membrane/Secretory Protein Synthesis: Since EIF4A2 selectively regulates membrane/secretory proteins, targeting this function could modulate cancer cell interaction with the microenvironment

• Immunomodulatory Applications:

  • B-cell Development Regulation: Given EIF4A2's critical role in B-cell development and proliferation, selective modulation could help treat B-cell malignancies or autoimmune disorders

  • Antibody Response Modulation: EIF4A2 is essential for both T-cell-dependent and T-cell-independent antibody responses, suggesting potential applications in vaccine enhancement or autoantibody suppression

  • Selective Translation Control: The distinct roles of EIF4A1 and EIF4A2 in immune responses suggest that selective targeting could achieve specific immunomodulatory effects

  • Ribosome Biogenesis Targeting: EIF4A2's role in 40S ribosome subunit formation presents a novel intervention point for diseases characterized by dysregulated ribosome biogenesis

• Diagnostic Applications:

  • Precision Pathology: EIF4A2 antibodies could be incorporated into diagnostic panels to classify tumors based on translation regulation profiles

  • Immune Function Assessment: Measuring EIF4A2 in immune cells might provide insights into immunodeficiencies or hyperactive immune states

  • Therapeutic Response Prediction: EIF4A2 expression patterns might predict response to translation-targeting therapies

• Research Tools Development:

  • Selective Inhibitors: Development of compounds that specifically target EIF4A2 over EIF4A1

  • Reporter Systems: Creation of tools to monitor EIF4A2 activity in real-time in disease models

  • Biomarker Validation: EIF4A2 antibodies for companion diagnostics in clinical trials

The distinct roles of EIF4A2 in controlling 40S ribosome biogenesis and selectively regulating membrane/secretory protein synthesis provide unique therapeutic opportunities . Future research focusing on the development of highly specific EIF4A2 modulators could lead to novel treatment strategies with potentially fewer side effects than broader translation inhibitors.